Stereotactic Radiation Therapy in Korea

At a Glance

Overview

Stereotactic radiation therapy is an umbrella term for two closely related techniques: Stereotactic Radiosurgery (SRS), used mainly for brain and skull-base targets, and Stereotactic Body Radiation Therapy (SBRT), used for tumors in the lung, liver, spine, prostate, and other body sites.

Both techniques use multiple, precisely angled radiation beams that converge on the tumor from outside the body. The convergence delivers a lethal dose to the tumor while each individual beam passes harmlessly through surrounding normal tissue.

Despite the word "surgery," no incisions are involved. The procedure is non-invasive and performed on an outpatient basis.

SRS typically treats in a single fraction. SBRT delivers the dose across 3–5 sessions (fractions), often on alternating days, which allows normal tissue to recover between treatments while still achieving ablative doses at the tumor.

Korea's oncology centers have deployed this technology for over two decades. CyberKnife systems, TrueBeam STX linear accelerators, and Tomotherapy platforms are all in active clinical use at major institutions in Seoul and beyond.

Am I a Candidate?

Stereotactic radiation therapy is considered when surgery carries high risk, when a tumor is in a sensitive or surgically inaccessible location, or when a patient prefers a non-invasive option.

Common indications include:

• Brain metastases (1–3 lesions, each typically under 3–4 cm)
• Primary brain tumors (acoustic neuroma, meningioma, arteriovenous malformation)
• Early-stage or medically inoperable lung cancer (Stage I–II, peripheral lesions)
• Liver tumors including hepatocellular carcinoma and oligometastatic disease
• Spinal metastases causing pain or at risk of cord compression
• Prostate cancer (SBRT as definitive or salvage treatment)
• Oligometastatic disease — limited metastases in kidney, adrenal, lymph nodes

Candidacy depends on:

• Tumor size and proximity to critical structures (optic nerves, brainstem, bowel)
• Overall performance status and prior radiation history
• Adequate imaging (high-resolution MRI or CT with contrast) to define the target
• A multidisciplinary tumor board review, which is standard at accredited Korean centers

Patients who have already received conventional radiation may still be candidates for stereotactic re-irradiation, though this requires careful dose review.

How the Procedure Works

The treatment unfolds across three distinct phases spread over several days.

Phase 1 — Simulation and Imaging (Day 1–2)

A dedicated planning CT scan is taken with the patient in the exact treatment position. For brain targets, a custom thermoplastic mask or stereotactic head frame immobilizes the head to sub-millimeter precision. For body targets, a vacuum body cradle is molded.

MRI is usually fused with the CT to delineate the tumor boundary with greater soft-tissue detail.

Phase 2 — Treatment Planning (Days 2–4)

A radiation oncologist contours the tumor (the gross tumor volume) and the surrounding critical structures that must be protected. A medical physicist then designs a beam arrangement — often 5 to 12 beams or non-coplanar arcs — to maximize dose within the target and minimize dose outside it.

This planning step can take 1–3 days.

Phase 3 — Delivery Sessions (Days 4–14 depending on fractions)

• The patient is positioned in the immobilization device.
• Image guidance (cone-beam CT or X-ray imaging) is performed before each fraction to verify the patient's position matches the plan.
• The treatment machine — CyberKnife, TrueBeam STX, or similar — delivers radiation from multiple angles over 30–90 minutes.
• The patient is awake and can communicate with the team throughout.
• After the final session, a follow-up imaging appointment is typically scheduled 4–8 weeks later to assess response.

Recovery Timeline

Stereotactic radiation therapy causes far less collateral tissue disruption than open surgery, so recovery is generally faster and milder.

During treatment sessions:

• Patients leave the department under their own power after each session.
• Mild fatigue is the most common side effect.
• Brain SRS may cause temporary headache or mild nausea on the day of treatment.

Days 1–7 post-final fraction:

• Fatigue is common but usually peaks within the first week.
• For brain targets: mild hair thinning may occur over the treatment area weeks later.
• For lung SBRT: occasional chest wall soreness if the beam path crosses ribs.
• For liver/prostate SBRT: mild gastrointestinal sensitivity or urinary frequency possible.

Weeks 2–6:

• Most patients return to normal daily activities within a few days.
• Heavy exercise or physically demanding work may be restricted for 2–3 weeks depending on the site.
• A follow-up imaging scan (MRI or CT, sometimes PET-CT) at 4–8 weeks is critical to assess the tumor's early response.

Months 2–6:

• Tumor may appear transiently larger on imaging before shrinking (radiation effect vs. progression — your oncologist will interpret this).
• Some patients experience delayed radiation effects at 3–6 months, especially near the brain; these are managed with steroids if symptomatic.

Korean centers typically provide a structured follow-up imaging schedule and telemedicine check-ins for international patients returning home.

Cost

Costs vary by hospital and case. Ask the hospital for a written, itemised estimate before you decide.

Why Korea

Korea's strengths in stereotactic radiation therapy reflect decades of institutional investment in radiation oncology infrastructure, research output, and structured oversight of international medical services.

Technology and clinical experience

Korea adopted CyberKnife technology in the early 2000s. By 2011, CyberKnife-based SBRT was formally reimbursed under the National Health Insurance Service, signaling regulatory recognition of its clinical value. Major centers in Seoul operate multiple high-energy linear accelerators with stereotactic capability, enabling them to schedule patients without long waiting periods.

Regulatory and accreditation framework

The Korea Health Industry Development Institute (KHIDI) tracks and supports inbound medical tourism. The KAHF (Korean Accreditation for Hospitals serving Foreign patients) designation — visible on the Medical Korea portal — identifies facilities that meet defined standards for international patient services including multilingual coordinators, patient rights, and quality systems.

The Ministry of Food and Drug Safety (MFDS) regulates the import, installation, and clinical use of radiotherapy devices in Korea, ensuring all treatment machines in use meet safety standards before patient exposure.

Cost and access

Waiting times at Korean cancer centers for stereotactic radiation are generally short compared to public health systems in Europe or Canada.

Seoul and Gangnam as oncology hubs

Seoul's Gangnam district and the broader Seocho corridor are home to several large general hospitals with dedicated radiation oncology departments. These institutions publish in international peer-reviewed oncology journals and participate in multinational clinical trials, reflecting active engagement with the global radiation oncology community.

Korea's medical tourism support infrastructure — visa-on-arrival medical visit pathways, multilingual hospital international centers, and platforms such as Medical Korea (medicalkorea.or.kr) — reduces logistical friction for patients traveling for cancer treatment.

Related Topics

Sources

• Survey of Stereotactic Body Radiotherapy in Korea — PMC
• CMS LCD: Stereotactic Radiation Therapy SRS and SBRT (L35076)
• Medical Korea — Accredited Hospitals (KAHF)
• KHIDI — Korea Health Industry Development Institute

International Patient Preparation Guides

Independent resources for international patients researching care in South Korea:

• Bringing Your Prescription Medications Into Korea: What to Know at Customs
• Sending Your Medical Records to Korea: A Data Privacy Guide

مستشفيات تقدّم Stereotactic Radiation Therapy